Autologous stem cell transplantation and purging in adult acute lymphoblastic leukaemia

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 4, 2002, Pages 675-693

  Grañena Batista, Albert ^a   Ferra Coll, Christelle ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Acute lymphoblastic leukaemia; Autologous haematopoietic progenitor transplantation; Bone marrow transplantation; Immunotherapy; Purging

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ADENOSINE TRIPHOSPHATE; ALKYLATING AGENT; ALKYLLYSOPHOSPHOLIPID; AMIFOSTINE; AMINOTHIOL; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CD22 ANTIGEN; CD52 ANTIGEN; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE DERIVATIVE; CYTARABINE; DIFFERENTIATION ANTIGEN; EDELFOSINE; EPIPODOPHYLLOTOXIN DERIVATIVE; ETHYTIOL; ETOPOSIDE; HEMOPOIETIC GROWTH FACTOR; IMMUNOTOXIN; IODINE 131; MAFOSFAMIDE; MELPHALAN; MONOCLONAL ANTIBODY; NEOMYCIN; RICIN A; UNINDEXED DRUG; VINCRISTINE; YTTRIUM 90; ALPHA INTERFERON; CYCLOSPORIN A; EPIPODOPHYLLOTOXIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VERAPAMIL;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW PURGING; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DRUG MEGADOSE; FREQUENCY ANALYSIS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVING DONOR; MAINTENANCE THERAPY; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOTHERAPY; REVIEW; RISK ASSESSMENT; TIME; TREATMENT INDICATION; TREATMENT OUTCOME; WHOLE BODY RADIATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CYTOGENETICS; DRUG ACTIVITY; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS LEUKEMIA EFFECT; HODGKIN DISEASE; IMMUNOREACTIVITY; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; SALVAGE THERAPY; T CELL DEPLETION;

EID: 23644443506     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0227     Document Type: Review

References (112)

1. Champlin R & Gale RP. Acute lymphoblastic leukemia: recent advances in biology and therapy. Blood 1989; 73: 2051-2066.
2. Hoelzer D & Gale RP. Acute lymphoblastic leukemia in adults: recent progress, future directions. Seminars in Hematology 1987; 24: 27-39.
3. Rivera GK, Buchanan G, Boyett GM et al. Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study. New England Journal of Medicine 1986; 315: 273-278.
4. Gaynor J, Chapman D, Little C et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital Experience since 1969. Journal of Clinical Oncology 1988; 6: 1014-1021.
5. Butturini A, Rivera GK, Bortin MM & Gale RP. Which treatment for childhood acute lymphoblastic leukaemia in second remission? Lancet 1987; i: 429-432.
6. Hoelzer D, Thiel E, Büchner T et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukaemia in adults. Blood 1988; 71: 123-131.
7. Weiss M, Maslak P, Feldman E et al. Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia with out the use of vincristine or prednisone. Journal of Clinical Oncology 1996; 14: 2480-2485.
8. Linker CA, Levitt LJ, O'Donnell M et al. Teniposide (VM-26) and ara-C in the treatment of adult acute lymphoblastic leukemia. Seminars in Oncology 1987; 14: 78-85.
9. Stryckmans PS, Otten J, Delbeke J et al. Comparison of chemotherapy with immunotherapy for maintenance of acute lymphoblastic leukemia in children and adults. Blood 1983; 62: 606-615.
10. Carlo-Stella C, Mangoni L, Dotti GP et al. Techniques for detection of minimal residual disease. Leukemia and Lymphoma 1995; 18: 75-80.
11. Cavé H, van der Werff ten Bosch J, Suciu S et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. New England Journal of Medicine 1998; 339: 591-598.
12. Fière D, Lepage E, Sebban C et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as post-remission therapy. Journal of Clinical Oncology 1993; 11: 1990-2001.
13. Blaise D, Gaspard MH, Stoppa AM et al. Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplantation 1990; 5: 7-12.
14. Kantarjian HM, Walters RS, Keating MJ et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard-and high-risk acute lymphocytic leukemia. Journal of Clinical Oncology 1990; 8: 994-1004.
15. Carey PJ, Proctor SJ, Taylor P et al. Autologous bone marrow transplantation for high-risk-grade lymphoid malignancy using melphalan-irradiation conditioning without marrow purging or cryopreservation. Blood 1991; 77: 1593-1598.
16. Powles R, Metha J, Singhal S et al. Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission. 50 cases of a single center. Bone Marrow Transplantation 1995; 16: 241-247.
17. Vey N, Blaise D, Stoppa AM et al. Bone marrow transplantation in 63 adult patints with acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplantation 1994; 14: 383-388.
18. Attal M, Blaise D, Marit G et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1995; 86: 1619-1628.
19. Laambertenghi Deliliers G, Mozzana R, Annaloro C et al. Long-term results of autologous bone marrow transplantation in adult acute lymphoblastic leukemia. Leukemia and Lymphoma 1993; 11: 419-425.
20. Weisdorf DJ, Nesbit ME, Ramsay NK et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft-versus-host disease. Journal of Clinical Oncology 1987; 5: 1348-1355.
21. Freund M, Diedrich H, Ganser A et al. Treatment of relapsed or refractory adult acute lymphocytic leukemia. Cancer 1992; 69: 709-716.
22. Kersey JH, Weisdorf D, Nesbit ME et al. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. New England Journal of Medicine 1987; 317: 461-467.
23. Proctor SJ, Hamilton PJ, Taylor P et al. A comparative study of combination chemotherapy versus marrow transplant in first remission in acute lymphoblastic leukemia. British Journal of Haematology 1988; 69: 35-39.
24. Helg C, Starobinski M, Jeannet M et al. Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leukemia and Lymphoma 1998; 29: 301-313.
25. Wingard JR, Piantadosi S, Santos GW et al. Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia. Journal of Clinical Ontology 1990; 8: 820-830.
26. Barret AJ, Horowitz MM, Gale RP et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989; 74: 862-871.
27. Martino R, Bellido M, Brunet S et al. Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia. Bone Marrow Transplantation 1998; 21: 1023-1027.
28. Arcese W, Amadori G, Meloni F et al. Allogeneic or autologous bone marrow transplantation for intensification of salvage therapy in patients with high-risk advanced acute lymphoblastic leukemia. Seminars in Hematology 1991; 3: 116-121.
29. Giona F, Annino L, Rondelli R et al. Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol. British Journal of Haematology 1997; 97: 896-903.
30. Soiffer RJ, Roy DC, Gonin R et al. Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse. Bone Marrow Transplantation 1993; 12: 243-251.
31. Bunin N, Carston M, Wall D et al. Unrelated marrow transplantation for children with acute leukemia in second remission. Blood 2002; 99: 3151-3157.
32. Weisdorf DJ, Billet AL, Hannan P et al. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood 1997; 90: 2962-2968.
33. Aversa. F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one full mismatched HLA haplotype. New England Journal of Medicine 1998; 339: 1186-1193.
34. Gluckman E, Rocha V, Boyer-Chammard A et al. Outcome of cord-blood transplantation from related and unrelated donors. New England Journal of Medicine 1997; 337: 373-381.
35. Morishima Y, Miyamura K, Kojima S et al. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex marrow leukemia cell purging with monoclonal antibodies and complement. Bone Marrow Transplant 1993; 11: 255-259.
36. Sierra J, Rovira M, Muñoz L et al. Autologous hematopoietic stem cell transplantation as treatment for adult acute lymphoblastic leukemia. In Dick KA & Keating A (eds) Autologous Blood and Marrow Transplantation. Proceedings of the Ninth International Symposium (Arlington, Texas), pp 72-83. Charlottesville: Virginia, 1999.
37. Canals C, Torrico C, Picón M et al. Immunomagnetic bone marrow purging in children with acute lymphoblastic leukemia. Journal of Hematotherapy 1997; 6: 261-268.
38. Doney K, Buckner CD, Fisher L et al. Autologous bone marrow transplantation for acute lymphoblastic leukaemia. Bone Marrow Transplantation 1993; 12: 315-321.
39. Sallan SE, Niemeyer CM, Billet AL et al. Autologous bone marrow transplantation for acute lymphoblastic leukemia. Journal of Clinical Oncology 1989; 7: 1594-1601.
40. Billet AL, Kornmehl E, Tarbell NJ et al. Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood 1993; 81: 1651-1657.
41. Maldonado MS, Díaz-Heredia C, Badell I et al. Autologous bone marrow transplantation with monoclonal antibody purged marrow for children with acute lymphoblastic leukemia in second remission. Bone Marrow Transplantation 1998; 22: 1043-1047.
42. Grañena A, Castellsagué X, Badell I et al. Autologous bone marrow transplantation for high.risk acute lymphoblastic leukemia: clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement. Bone Marrow Transplantation 1999; 24: 621-627.
43. Colleselli P, Rossetti F, Messina C et al. Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia in remission: first choice of isolated extramedullary relapse? Bone Marrow Transplantation 1994; 14: 821-825.
44. Messina C, Valsecchi MG, Arico M et al. Autologous bone marrow transplantation for treatment of isolated central nervous system relapse of childhood acute lymphoblastic leukemia. AIEOP/FONOPTMO group. Associzone Italiana Emato-Oncologia Pediatrica. Bone Marrow Transplantation 1998; 21: 9-14.
45. Woods WG, Ramsay NKC, Weisdorf R et al. Bone marrow transplantation for acute lymphoblastic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing regimens. Bone Marrow Transplant 1990; 6: 9-16.
46. Krance RA, Forman SJ & Blume KJ. Total body irradiation and high dose teniposide: a pilot study in bone marrow transplantation for patients with relapsed acute lymphoblastic leukemia. Cancer Treatment Reports 1987; 71: 645-647.
47. Raemaekers J, de Witte T, Schattenberg A & vander Lely N. Prevention of leukemic relapse after transplantation with lymphocyte depleted marrow by intensification of the conditioning regimen with a 6-day continuous infusion of anthracyclines. Bone Marrow Transplantation 1989; 4: 167-171.
48. Brochstein JA, Kernan NA, Groshen S et al. Allogeneic bone marrow transplantation after hyperfractionated total body irradiation and cyclophosphamide in children with acute leukemia. New England Journal of Medicine 1987; 317: 1618-1624.
49. Underzo C, Rondelli R, Dini G et al. High-dose vincristine, fractionated total-body irradiation and cyclophosphamide as conditioning regimen in allogeneic and autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission: a 7-year Italian multicentre study. British Journal of Haematology 1995; 89: 790-797.
50. Vogler WR, Berdel WE, Olson AC et al. Autologous bone marrow purging in acute leukemia with marrow purged with Alkyl-Lysophospholipid. Blood 1992; 80: 1423-1429.
51. Clift RA, Buckner CD, Appelbaum et al. Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplant during first remission of acute myeloid leukemia. Blood 1998; 92: 1455-1456.
52. Chao NJ, Stein AS, Long GD et al. Busulfan/etoposide - initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute non-lymphoblastic leukemia. Blood 1993; 81: 319-323.
53. Metha J, Powles R, Treleaven J et al. Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia: long-term follow-up. Leukemia and Lymphoma 1997; 25: 479-486.
54. Flinn IW & Lazarus HM. Monoclonal antibodies and autologous stem cell transplantation for lymphoma. Bone Marrow Transplantation 2001; 27: 565-569.
55. Metha J, Powles R, Horton C et al. Factors affecting engraftment and hematopoietic recovery after unpurged autographing in acute leukemia. Bone Marrow Transplantation 1996; 18: 319-324.
56. Houtenbos I, Bracho F, Devenport V et al. Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia: a novel combined approach consisting of ex vivo marrow purging, modulation of multi-drug resistance, induction of autograft vs leukemia effect, and post-transplant immuno and chemotherapy (PTIC). Bone Marrow Transplantation 2001; 27: 145-153.
57. Lemoli RM, Visani G, Leopardi G et al. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. Bone Marrow Transplantation 1999; 23: 235-241.
58. Carella AM, Pollicardo N, Pungolino et al. Mobilization of cytogenetically 'normal' progenitors cell by intensive chemotherapy for chronic myeloid and acute lymphoblastic leukemia. Leukemia and Lymphoma 1993; 9: 477-483.
59. Carella AM, Dejana A, Lerma E et al. In vivo mobilization of kariotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. British Journal of Haematology 1996; 95: 127-130.
60. Atta J, Fauth F, Keyser M et al. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia vs peripheral blood stem cells by semiquantitative polymerase chain reaction. Bone Marrow Transplantation 2000; 25: 97-104.
61. van Rhee F, Marks DI, Lin F et al. Quantification of residual disease in Philadelphia positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia 1995; 9: 329-335.
62. Fefer A, Cheever MA & Greenberg PD. Identical-twin (Syngeneic) marrow transplantation for hematologic cancers. Journal of the National Cancer Institute 1986; 76: 1269-1273.
63. Martin H, Atta J, Zumpe P et al. Purging of peripheral blood stem cells yields BCR-ABL-negative autographs in patients with BCR-ABL-positive acute lymphoblastic leukemia. Experimental Hematology 1995; 23: 1612-1618.
64. Atta J, Martin H, Bruecher J et al. Residual leukemia and immunomagnetic bead purging in patients with BCR-ABL-positive acute lymphoblastic leukemia. Bone Marrow Transplantation 1996; 18: 541-548.
65. + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.
66. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-86.
67. Garcia J, Puntí C, Picon M et al. Bone marrow purging in acute lymphoblastic leukemia: biological and clinical features. Journal of Hematotherapy 1994; 3: 203-211.
68. Uckun FM, Kersey JH, Vallera DA et al. Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxin plus 4-hydroperoxycyclophosphamide for marrow purging. Blood 1990; 9: 1723-1733.
69. Uckun FM, Kersey JH, Haake R et al. Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9 and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging. Blood 1992; 4: 1094-1104.
70. Douay H, Hu C, Giarratana MC et al. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood 1995; 86: 2849-2855.
71. Rosenfeld C, Shadduck RK, Przepiorka D et al. Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purged marrows for acute nonlymphocytic leukemia in remission or early relapse. Blood 1989; 74: 1159-1164.
72. Rowley SD, Zuehlsdorf M, Braine HG et al. GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow. Blood 1987; 70: 271-275.
73. Gilmore MAE, Hamon MD et al. Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukemia in first complete remision. Bone Marrow Transplantation 1991; 8: 19-26.
74. Laporte J Ph, Douay L, Lopez M et al. One hundred twenty-five adult patients with primary acute leukemia autographed with marrow purged by mafosfamide: a 10-year single institution experience. Blood 1994; 84: 3810-3818.
75. Lemoli RM & Gulati SC. In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors. Experimental Hematology 1990; 18: 1008-1012.
76. Hatta Y, Iotoh T, Baba M et al. Purging in autologous hematopoietic stem cell transplantation using adenosine triphosphate (ATP) and 4-hydroperoxycyclophosphamide. Leukemia Research 2002; 26: 477-482.
77. Kaiser H, Stuart RK, Brookmeyer R et al. Autologous bone marrow transplantation in acute leukemia: A phase I study of in vitro treatment of marrow with 4-hydroperoxycyclophosphamide to purge tumor cells. Blood 1985; 65: 1504-1510.
78. Yeager AM, Rowley SD, Kaizer H & Santos GW. Ex vivo chemopurging of autologous bone marrow with 4-hydroperoxycyclophosphamide to eliminate occult leukemic cells. Laboratory and clinical observations. American Journal of Pediatric Hematology/Oncology 1990; 12: 245-256.
79. Gonzales-Chambers R, Przepiorka D, Shadduck RK et al. Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow for acute lymphoblastic leukemia. Medical and Pediatric Oncology 1991; 19: 160-164.
80. Vogler WR, Whigham EA, Somberg LB et al. The effect of alkyl-lysophospholipids on tritiated thymidineincorporation and clonogenicity in vitro of normal and leukemic human cells. Experimental Hematology 1984; 12: 569-574.
81. Martens AC & Hagenbeek A. Amifostine (WR 2721) for dose escalation in marrow-ablative treatment of leukemia. European Journal of Cancer 1999; 35: 634-640.
82. Shpall EJ, Stemmer SM, Hami L et al. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 1994; 83: 3132-3137.
83. Muirhead M, Martin PJ, Torok-Storb B et al. Use of an antibody-ricin A chain conjugate to delete neoplastic B cells from human bone marrow. Blood 1983; 62: 327-332.
84. Katz FE, Janossy G, Cumber A et al. Elimination of T cells from human peripheral blood and bone marrow using a cocktail of three anti-T cell immunotoxins. British Journal of Haematology 1987; 67: 407-411.
85. Preijers FW, De Witte T, Wessels J et al. Autologous transplantation of bone marrow purged in vitro with anti-CD-7 (WTI-) ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma. Blood 1989; 74: 1152-1158.
86. Anderson KC, Ritz J, Takvorian T et al. Hematologic engraftment and immune reconstitution posttransplantation with anti-BI purged autologous bone marrow. Blood 1987; 69: 597-604.
87. Simonsson B, Burnett AK, Prentice HG et al. Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia. Leukemia 1989; 9: 631-636.
88. Ramsay N, LeBien T, Nesbit M et al. Autologous bone marrow transplantation for patients with acute lymphoblastic leukemia in second or subsequent remision: resuls of bone marrow treated with monoclonal antibodies BA-1, BA-2 and BA-3 plus complement. Blood 1985; 66: 508-513.
89. Schmid H, Henze G, Schwerdferger R et al. Fractionated total body irradiation and high-dose VP-16 with purged autologous bone marrow rescue for children with high risk relapsed acute lymphoblastic leukemia. Bone Marrow Transplantation 1993; 12: 597-602.
90. Vervoordeldonk SF, van den Berg H, von dem Borne AE et al. Optimization of purging of autologous bone marrow grafts for children with precursor B acute lymphoblastic leukemia. Journal of Hematotherapy 1997; 6: 495-500.
91. Wang MY, Fodstad O, Ludwig WD et al. An effective, direct immunomagnetic procedure for purging acute lymphoblastic leukemia cells from human bone marrow. Pathology Oncology Research 1995; 1: 32-37.
92. Gribben JG, Saporito L, Barber M et al. Bone marrows of non-Hodgkin's lymphoma patients with bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Blood 1992; 80: 1083-1089.
93. Ritz J, Sallan SE, Bast RC et al. Autologous bone marrow transplantation in CALLA positive acute lymphoblastic leukemia after in vitro treatment with J5 monoclonal antibody and complement. Lancet 1982; 2: 60-63.
94. George AA, Franklin J, Kerkof K et al. Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia. Blood 2001; 98: 3925-3930.
95. LeBien TW, Anderson JM, Valleera DA & Uckun FM. Increased efficacy in selective elimination of leukemic cell line clonogenic cells by a combination of monoclonal antibodies BA-1, BA-2, BA-3 + complement and mafosfamide (ASTA Z 7557). Leukemia Research 1986; 10: 139-143.
96. Uckun FM, Stong RC, Youle RJ & Vallera DA. Combined ex vivo treatment with immunotoxins and mafosfamide: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts. Journal of Immunology 1985; 134: 3504-3515.
97. Charak BS, Malloy B, Agah R & Mazumder A. A novel approach to purging of leukemia by activation of bone marrow with interleukin-2. Bone Marrow Transplantation 1990; 6: 193-198.
98. Meehan KR, Badros A, Frankel SR et al. A pilot study evaluating interleukin-2-activated hematopoietic stem cell transplantation for hematologic malignancies. Journal of Hematotherapy 1997; 6: 457-464.
99. Meehan KR, Wu A, Hassan R et al. Ex vivo cytokine activation of peripheral blood stem cells: a potential role for adoptive cellular immunotherapy. Journal of Hematotherapy Stem Cell Research 2001; 10: 283-290.
100. Lunger SM, O'Brien SG, Ratajczak J et al. Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood 2002; 99: 1150-1158.
101. De Fabritiis P, Petti MC, Montefusco E et al. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 1998; 91: 3156-3162.
102. Gruhn B, Hafer R, Kosmehl H et al. Cyclosporin A-induced graft-versus-host disease following autologous bone marrow and stem cell transplantation in hematological malignancies of childhood. Bone Marrow Transplantation 1998; 21: 901-907.
103. Tatanatharathorn V, Uberti J, Karanes C et al. Phase I study of alpha-inerferon augmentation of cyclosporine-incluced graft versus host disease in recipients of autologous bone marrow transplantation. Bone Marrow Transplantation 1994; 13: 625-630.
104. Rosenberg SA, Grimm EA, McGrogan M et al. Biological activity of recombinant interleukin-2 produced in E. coli. Science 1984; 223: 1412-1414.
105. Lauria F, Raspadori D, Rondelli D et al. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and survival. Leukemia 1994; 8: 724-728.
106. Higuchi CM, Thompson JA, Petersen FB et al. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991; 77: 2561-2568.
107. Blaise D, Olive D, Stoppa AM et al. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76: 1092-1097.
108. Robinson N, Benyunes MC, Thompson JA et al. Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study. Bone Marrow Transplantation 1997; 19: 435-442.
109. Klingemann HG & Phillips GL. Is there a place for immunotherapy with interleukin-2 to prevent relapse after autologous stem cell transplantation for acute leukemia? Leukemia and Lymphoma 1995; 16: 397-405.
110. Weisdorf DJ, Anderson PM, Blazar BR et al. Interleukin-2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia. A phase I study. Transplantation 1993; 55: 61-66.
111. Meloni G, Foa R, Tosti S et al. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study. Leukemia 1992; 6: 780-785.
112. Tiley C, Powles R, Treleaven J et al. Feasibility and efficacy of maintenance chemotherapy following autologous bone marrow transplantation for first remission acute lymphoblastic leukemia. Bone Marrow Transplantation 1993; 12: 449-455.